Glycogen synthase kinase 3β inhibition synergizes with PARP inhibitors through the induction of homologous recombination deficiency in colorectal cancer
Open Access
- 15 February 2021
- journal article
- research article
- Published by Springer Nature in Cell Death & Disease
- Vol. 12 (2) , 1-18
Abstract
Monotherapy with poly ADP-ribose polymerase (PARP) inhibitors results in a limited objective response rate (≤60% in most cases) in patients with homologous recombination repair (HRR)-deficient cancer, which suggests a high rate of resistance in this subset of patients to PARP inhibitors (PARPi). To overcome resistance to PARPi and to broaden their clinical use, we performed high-throughput screening of 99 anticancer drugs in combination with PARPi to identify potential therapeutic combinations. Here, we found that GSK3 inhibitors (GSK3i) exhibited a strong synergistic effect with PARPi in a panel of colorectal cancer (CRC) cell lines with diverse genetic backgrounds. The combination of GSK3β and PARP inhibition causes replication stress and DNA double-strand breaks, resulting in increased anaphase bridges and abnormal spindles. Mechanistically, inhibition or genetic depletion of GSK3β was found to impair the HRR of DNA and reduce the mRNA and protein level of BRCA1. Finally, we demonstrated that inhibition or depletion of GSK3β could enhance the in vivo sensitivity to simmiparib without toxicity. Our results provide a mechanistic understanding of the combination of PARP and GSK3 inhibition, and support the clinical development of this combination therapy for CRC patients.Keywords
This publication has 65 references indexed in Scilit:
- Aberrant Glycogen Synthase Kinase 3β Is Involved in Pancreatic Cancer Cell Invasion and Resistance to TherapyPLOS ONE, 2013
- PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP InhibitionCancer Discovery, 2012
- Canonical Wnt signaling regulates Slug activity and links epithelial–mesenchymal transition with epigenetic Breast Cancer 1, Early Onset (BRCA1) repressionProceedings of the National Academy of Sciences, 2012
- Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and LymphomasCancer Research, 2011
- Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibitionNature Medicine, 2011
- Glycogen synthase kinase 3β inhibition enhances repair of DNA double-strand breaks in irradiated hippocampal neuronsNeuro-Oncology, 2011
- GSK-3: Functional Insights from Cell Biology and Animal ModelsFrontiers in Molecular Neuroscience, 2011
- Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial GlioblastomaJournal of Clinical Oncology, 2010
- A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomasNeuro-Oncology, 2010
- Deregulated GSK3β activity in colorectal cancer: Its association with tumor cell survival and proliferationBiochemical and Biophysical Research Communications, 2005